1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc.

ARCT
Arcturus Therapeutics Holdings Inc.US flagNASDAQ Global Market
15.82
USD
+0.26
- -
449.65MMarket Cap

Total Valuation

Arcturus Therapeutics Holdings Inc. carries a market capitalization of 449.65M, placing it among publicly traded companies globally. Its enterprise value stands at 22.45M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap449.65M
Enterprise Value22.45M

Share Statistics

Arcturus Therapeutics Holdings Inc. currently has 28.42M shares outstanding.

Shares Outstanding28.42M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 10.06, and the price-to-book ratio stands at 1.11.

PE RatioN/A
PS Ratio10.06
PB Ratio1.11
P/TBV Ratio1.11
P/FCF Ratio-2.59
P/OCF Ratio-2.59

Enterprise Valuation

EV / Sales1.20
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Arcturus Therapeutics Holdings Inc. maintains a current ratio of 5.88, meaning it holds 5.9x the short-term assets needed to cover near-term liabilities.

Current Ratio5.88
Quick Ratio5.76
Debt / Equity13.35
Debt / EBITDA-0.23
Interest CoverageN/A

Financial Efficiency

Return on Equity (ROE)-46.31
Return on Assets (ROA)-34.96
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory TurnoverN/A

Taxes

Income Tax-4,000.00
Effective Tax RateN/A

Stock Price Statistics

Arcturus Therapeutics Holdings Inc.'s stock has declined approximately -11.37255% over the past 52 weeks. The 50-day moving average sits at 8.58, while the 200-day moving average is 7.71.

Beta (5Y)N/A
52-Week Price Change-11.37255%
50-Day Moving Average8.58
200-Day Moving Average7.71
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Arcturus Therapeutics Holdings Inc. generated 18.72M in revenue and converted that into -93.28M in net income, yielding earnings per share of -3.33. EBITDA reached -99.55M, while operating income came in at -102.29M.

Revenue18.72M
Gross ProfitN/A
Operating Income-102.29M
Pretax Income-93.28M
Net Income-93.28M
EBITDA-99.55M
EBIT-102.29M
Earnings Per Share (EPS)-3.33

Balance Sheet

Arcturus Therapeutics Holdings Inc. holds 191.48M in cash and equivalents against 22.93M in total debt, resulting in a net debt position of -191.48M. Total book value stands at 171.81M, with working capital of 163.63M providing operational flexibility.

Cash & Cash Equivalents191.48M
Total Debt22.93M
Net Debt-191.48M
Equity (Book Value)171.81M
Book Value Per Share6.04
Working Capital163.63M

Cash Flow

Arcturus Therapeutics Holdings Inc. produced -72.73M in operating cash flow over the past twelve months. After subtracting -93,000.00 in capital expenditures, free cash flow totaled -72.82M - equivalent to -2.60 per share.

Operating Cash Flow-72.73M
Capital Expenditures-93,000.00
Free Cash Flow-72.82M
FCF Per Share-2.60

Margins

Arcturus Therapeutics Holdings Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -546.33 and net profit margin of -498.16 provide insight into operational efficiency.

Gross Margin100.00
Operating Margin-546.33
Pretax Margin-498.18
Profit Margin-498.16
EBITDA Margin-531.67

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-6.77
FCF Yield-38.55

Stock Splits

Arcturus Therapeutics Holdings Inc.'s most recent stock split took place on November 16, 2017 with a 7:1 split ratio.

Last Split Date11/16/2017
Split Ratio7:1

Scores

Arcturus Therapeutics Holdings Inc. posts an Altman Z-Score of -1.89, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-1.89